TriangleNilotinib (NCT04903119)
Nilotinib trial for BRAF V600 Metastatic or Unresectable Melanoma (NCT04903119). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with metastatic or unresectable melanoma that has a BRAF V600 mutation and has come back after BRAF and MEK inhibitor therapy.
The idea: add nilotinib, a daily pill at rising doses, to a fixed regimen of dabrafenib and trametinib, or of encorafenib and binimetinib. The study looks for the highest safe dose of nilotinib in the combination.
This phase 1 study plans 30 patients. At the University of Kentucky, Ruta Arays and Rina Plattner lead it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.